Open AccessP1247: GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS‐PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES
Author(s) -
Yusuf I.,
Guimond D.,
Naiman Z.,
Schiff T.,
Clemons B.,
Paulson B.,
Hou K.,
Taylor Meadows K.,
Rose M.,
Carter L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847852.69497.6d
Subject(s) - bruton's tyrosine kinase , ibrutinib , kinome , pharmacology , chemistry , kinase , tyrosine kinase , biochemistry , cancer research , biology , immunology , signal transduction , leukemia , chronic lymphocytic leukemia